Cardium Therapeutics Inc. Comm (CRXM) 0.2696 $CRXM
Post# of 273319
Posted On: 09/22/2016 5:02:16 PM
Cardium Therapeutics Inc. Comm (CRXM) 0.2696 $CRXM
Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
PR Newswire - Mon Sep 12, 8:00AM CDT
Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), today announced that the U.S. FDA Center for Biologics Evaluation and Research (CBER) has cleared the Angionetics' Generx® [Ad5FGF-4] angiogenic gene therapy cardiac biologic product candidate for Phase 3 clinical study as a new, single dose, treatment for patients with myocardial ischemia and refractory angina due to advanced coronary artery disease (the AFFIRM study). The Ad5FGF-4 product candidate is being developed by Angionetics as a new and innovative biologic tool for use by the interventional cardiology community. For more information about the Generx clinical development program, visit www.angionetics.com
ARCA biopharma (ABIO): Leveraging Genetic Targeting to Better Treat Cardiovascular Disease
ACCESSWIRE - Tue Sep 15, 10:20AM CDT
REDONDO BEACH, CA / ACCESSWIRE / September 15, 2015 / Cardiovascular disease is responsible for one-in-four deaths each year in the United States, or roughly 610,000 deaths each year, making it the leading cause of death in both men and women, according to the Centers for Disease Control. Despite causing more deaths than cancer each year, many cardiovascular drugs are based on loose associations rather than the precision genetic targeting that underlies many oncology drugs.
CYTK: 8.83 (-0.02), BSX: 23.73 (unch), MDT: 87.82 (+0.68), AZN: 34.28 (+0.53), PFE: 34.15 (-0.13), LH: 137.83 (+1.11), ABIO: 2.95 (+0.05), BMY: 56.42 (+0.49)
Taxus Cardium Announces Agreement With Dr. Reddy's Laboratories To Co-Develop, Market & Sell Generx Angiogenic Microvascular Gene Therapy In Certain International Markets
PR Newswire - Tue Apr 07, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (trading symbol: CRXM) today announced that it has entered into a binding term sheet with Dr. Reddy's Laboratories Ltd. (NYSE: RDY) for an exclusive territorial license covering the co-development, marketing and sales of the Generx® [Ad5FGF-4] angiogenic microvascular gene therapy Phase 3 product candidate for patients with refractory angina, and myocardial ischemia due to cardiac microvascular insufficiency (CMI).
RDY: 47.70 (+0.91)
Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
PR Newswire - Tue Jan 27, 8:00AM CST
Taxus Cardium Pharmaceuticals Group (Symbol: CRXM) today announced a presentation at the 2015 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The review and clinical update, entitled "Progress in Angiogenic Gene Therapy for Coronary Artery Disease" was presented by the Company's Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D.
Taxus Cardium Elects Three New Board Members Including PRC Strategic Investor Jiayue Zhang, John Wallace, U.S. Equity Trading Services Executive, And Wei-Wei Zhang, International Gene Therapy Pioneer
PR Newswire - Thu Jan 15, 8:00AM CST
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the election of the following three new directors: Mr. Jiayue Zhang, President of Shanxi Taxus Pharmaceuticals Co. Ltd. (Shanxi Taxus) and Shenzhen Frontsea Taxus Industry Capital Management, Mr. John F. Wallace, President of Philadelphia Financial Services LLC and former Chairman of the Philadelphia Stock Exchange, and Wei-Wei Zhang, M.D., Ph.D. an international pioneer in the research and commercialization of gene-based therapeutics, as new members of the Company's Board of Directors.
Taxus Cardium Reports On Third Quarter 2014 Results And Corporate Development Activities
PR Newswire - Thu Nov 20, 8:00AM CST
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) and its advanced regenerative medicine business units today reported results for the third quarter ended September 30, 2014 and corporate development activities.
Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
PR Newswire - Mon Sep 12, 8:00AM CDT
Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), today announced that the U.S. FDA Center for Biologics Evaluation and Research (CBER) has cleared the Angionetics' Generx® [Ad5FGF-4] angiogenic gene therapy cardiac biologic product candidate for Phase 3 clinical study as a new, single dose, treatment for patients with myocardial ischemia and refractory angina due to advanced coronary artery disease (the AFFIRM study). The Ad5FGF-4 product candidate is being developed by Angionetics as a new and innovative biologic tool for use by the interventional cardiology community. For more information about the Generx clinical development program, visit www.angionetics.com
ARCA biopharma (ABIO): Leveraging Genetic Targeting to Better Treat Cardiovascular Disease
ACCESSWIRE - Tue Sep 15, 10:20AM CDT
REDONDO BEACH, CA / ACCESSWIRE / September 15, 2015 / Cardiovascular disease is responsible for one-in-four deaths each year in the United States, or roughly 610,000 deaths each year, making it the leading cause of death in both men and women, according to the Centers for Disease Control. Despite causing more deaths than cancer each year, many cardiovascular drugs are based on loose associations rather than the precision genetic targeting that underlies many oncology drugs.
CYTK: 8.83 (-0.02), BSX: 23.73 (unch), MDT: 87.82 (+0.68), AZN: 34.28 (+0.53), PFE: 34.15 (-0.13), LH: 137.83 (+1.11), ABIO: 2.95 (+0.05), BMY: 56.42 (+0.49)
Taxus Cardium Announces Agreement With Dr. Reddy's Laboratories To Co-Develop, Market & Sell Generx Angiogenic Microvascular Gene Therapy In Certain International Markets
PR Newswire - Tue Apr 07, 8:00AM CDT
Taxus Cardium Pharmaceuticals Group Inc. (trading symbol: CRXM) today announced that it has entered into a binding term sheet with Dr. Reddy's Laboratories Ltd. (NYSE: RDY) for an exclusive territorial license covering the co-development, marketing and sales of the Generx® [Ad5FGF-4] angiogenic microvascular gene therapy Phase 3 product candidate for patients with refractory angina, and myocardial ischemia due to cardiac microvascular insufficiency (CMI).
RDY: 47.70 (+0.91)
Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
PR Newswire - Tue Jan 27, 8:00AM CST
Taxus Cardium Pharmaceuticals Group (Symbol: CRXM) today announced a presentation at the 2015 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The review and clinical update, entitled "Progress in Angiogenic Gene Therapy for Coronary Artery Disease" was presented by the Company's Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D.
Taxus Cardium Elects Three New Board Members Including PRC Strategic Investor Jiayue Zhang, John Wallace, U.S. Equity Trading Services Executive, And Wei-Wei Zhang, International Gene Therapy Pioneer
PR Newswire - Thu Jan 15, 8:00AM CST
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the election of the following three new directors: Mr. Jiayue Zhang, President of Shanxi Taxus Pharmaceuticals Co. Ltd. (Shanxi Taxus) and Shenzhen Frontsea Taxus Industry Capital Management, Mr. John F. Wallace, President of Philadelphia Financial Services LLC and former Chairman of the Philadelphia Stock Exchange, and Wei-Wei Zhang, M.D., Ph.D. an international pioneer in the research and commercialization of gene-based therapeutics, as new members of the Company's Board of Directors.
Taxus Cardium Reports On Third Quarter 2014 Results And Corporate Development Activities
PR Newswire - Thu Nov 20, 8:00AM CST
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) and its advanced regenerative medicine business units today reported results for the third quarter ended September 30, 2014 and corporate development activities.
(0)
(0)